To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT05814393
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT05814393
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05814393. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-03 (actual); primary completion 2024-05-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Treatment Period(JW0201)
- Intervention (Drug)
- Treatment Period(Placebo)
- Intervention (Drug)
- Extension Period(JW0201)
- Lead sponsor
- JW Pharmaceutical
Record details
- Record id
cardio:ct-nct05814393- Content hash
c15329ee1c0552293a10062fcfece22862213510c62ac49095d31d8a4c306cdf